Abstract
Up to now, a large number of HPV therapeutic vaccines have been developed targeting E6 and E7 oncoproteins including peptide/protein-based vaccines, live vector vaccines, cell-based vaccines and nucleic acid-based vaccines; each with advantages and disadvantages. These vaccines control HPV infection through cellmediated immunity in preclinical and clinical trials, e.g., adoptive T-cell therapy in patients with advanced cervical cancer and/or DNA-based vaccine in HPV-16 or HPV- 18 positive CIN clinical trials. In this chapter, the potential use of therapeutic vaccines as safe and effective pharmacological tools in cervical diseases will be explained, focusing on vaccines that have been tested in clinical trials.
Keywords: HPV, Immunogenicity, Safety , Therapeutic vaccine.
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Diabetes Reviews
Current Neurovascular Research
Current Respiratory Medicine Reviews
Current Pediatric Reviews
Infectious Disorders - Drug Targets
Current Stem Cell Research & Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets
Current Alzheimer Research
Current Aging Science
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents